{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:05:29Z","timestamp":1782817529274,"version":"3.54.5"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.bioorg.2022.105966","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T11:09:27Z","timestamp":1655204967000},"page":"105966","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["New phthalimide-based derivatives as EGFR-TK inhibitors: Synthesis, biological evaluation, and molecular modeling study"],"prefix":"10.1016","volume":"127","author":[{"given":"Nayera I.","family":"Mansour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selwan M.","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia S.","family":"El-Gohary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naglaa I.","family":"Abdel-Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein I.","family":"El-Subbagh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam A.","family":"Ghaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2022.105966_b0005","first-page":"579","article-title":"Summary-Cancer cell metastasis session","volume":"2","author":"Bagi","year":"2002","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"10.1016\/j.bioorg.2022.105966_b0010","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/bjs.11098","article-title":"Population-based study of surgical treatment with and without tumour resection in patients with locally recurrent rectal cancer","volume":"106","author":"Westberg","year":"2019","journal-title":"Br. J. Surg."},{"issue":"6","key":"10.1016\/j.bioorg.2022.105966_b0015","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1073\/pnas.1818357116","article-title":"Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma","volume":"116","author":"Zhao","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2022.105966_b0020","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40814-016-0079-6","article-title":"Development and feasibility of a swallowing intervention package (SiP) for patients receiving radiotherapy treatment for head and neck cancer-the SiP study protocol","volume":"2","author":"Wells","year":"2016","journal-title":"Pilot Feasibility Stud."},{"issue":"2","key":"10.1016\/j.bioorg.2022.105966_b0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/35052073","article-title":"Untangling the ErbB signalling network","volume":"2","author":"Yarden","year":"2001","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.bioorg.2022.105966_b0030","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: The complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.bioorg.2022.105966_b0035","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.ijrobp.2003.11.041","article-title":"Review of epidermal growth factor receptor biology","volume":"59","author":"Herbst","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.bioorg.2022.105966_b0040","doi-asserted-by":"crossref","first-page":"5268","DOI":"10.1158\/1078-0432.CCR-05-1554","article-title":"The epidermal growth factor receptor pathway: a model for targeted therapy","volume":"12","author":"Scaltriti","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.bioorg.2022.105966_b0045","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jhep.2004.08.024","article-title":"Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma","volume":"41","author":"H\u00f6pfner","year":"2004","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105966_b0050","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1093\/annonc\/mdi006","article-title":"Impact of EGFR expression on colorectal cancer patient prognosis and survival","volume":"16","author":"Spano","year":"2005","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2022.105966_b0055","doi-asserted-by":"crossref","first-page":"8118","DOI":"10.1200\/JCO.2005.03.0130","article-title":"Epidermal growth factor expression in breast cancer","volume":"23","author":"Nguyen","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bioorg.2022.105966_b0060","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/PAI.0000000000000932","article-title":"Nuclear EGFR Expression Is Associated with Poor Survival in Laryngeal Carcinoma","volume":"29","author":"Mariji\u0107","year":"2021","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"issue":"2","key":"10.1016\/j.bioorg.2022.105966_b0065","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/sj.bjc.6601536","article-title":"Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence","volume":"90","author":"Hernes","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2022.105966_b0070","first-page":"760","article-title":"Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma","volume":"64","author":"Oh","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2022.105966_b0075","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0959-8049(01)00231-3","article-title":"EGFR and cancer prognosis","volume":"37","author":"Nicholson","year":"2001","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.bioorg.2022.105966_b0080","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1021\/mp100179t","article-title":"Virtual screening of selective multitarget kinase inhibitors by combinatorial support vector machines","volume":"7","author":"Ma","year":"2010","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bioorg.2022.105966_b0085","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1358\/dof.1999.024.05.858622","article-title":"Small molecule inhibitors of receptor tyrosine kinases","volume":"24","author":"Boschelli","year":"1999","journal-title":"Drug Future"},{"key":"10.1016\/j.bioorg.2022.105966_b0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115674","article-title":"New series of isoxazole derivatives targeting EGFR-TK: Synthesis, molecular modeling and antitumor evaluation","volume":"28","author":"Warda","year":"2020","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.105966_b0095","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0163-7258(02)00179-1","article-title":"Protein kinases as targets for anticancer agents: from inhibitors to useful drugs","volume":"93","author":"Fabbro","year":"2002","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105966_b0100","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nrc2559","article-title":"Targeting cancer with small molecule kinase inhibitors","volume":"9","author":"Zhang","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2022.105966_b0105","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/cb500129t","article-title":"Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery","volume":"9","author":"Zhao","year":"2014","journal-title":"ACS Chem. Biol."},{"issue":"16","key":"10.1016\/j.bioorg.2022.105966_b0110","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1016\/j.bmc.2016.05.063","article-title":"Toward discovery of mutant EGFR inhibitors; Design, synthesis and in vitro biological evaluation of potent 4-arylamino-6-ureido and thioureido-quinazoline derivatives","volume":"24","author":"Mowafy","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.105966_b0115","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/BF00124317","article-title":"Modelling study of protein kinase inhibitors: Binding mode of staurosporine and origin of the selectivity of CGP 52411","volume":"9","author":"Furet","year":"1995","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105966_b0120","doi-asserted-by":"crossref","DOI":"10.1038\/srep16750","article-title":"Targeting kinases with anilinopyrimidines: discovery of N-phenyl-N\u2019-[4-(pyrimidin-4-ylamino)phenyl]urea derivatives as selective inhibitors of class III receptor tyrosine kinase subfamily","volume":"5","author":"Gandin","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2022.105966_b0125","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1097\/JTO.0b013e3181f1c7b0","article-title":"Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva lung cancer survival treatment study","volume":"5","author":"Reck","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2022.105966_b0130","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.clinthera.2005.10.014","article-title":"Erlotinib: small-molecule targeted therapy in the treatment of non small-cell lung cancer","volume":"27","author":"Smith","year":"2005","journal-title":"Clin. Ther."},{"issue":"6","key":"10.1016\/j.bioorg.2022.105966_b0135","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1517\/14656566.6.6.985","article-title":"Gefitinib in non-small cell lung cancer","volume":"6","author":"Tamura","year":"2005","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.bioorg.2022.105966_b0140","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/ijms20010028","article-title":"C, Imbriano, Potent anti-cancer properties of phthalimide-based curcumin derivatives on prostate tumor cells","volume":"20","author":"Belluti","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.bioorg.2022.105966_b0145","doi-asserted-by":"crossref","DOI":"10.2174\/1570180814666170127164759","article-title":"Synthesis and biological evaluation of 1,3,4-thiadiazole linked phthalimide derivatives as anticancer agents","volume":"14","author":"Rezaei","year":"2017","journal-title":"Lett. Drug Des. Discov."},{"key":"10.1016\/j.bioorg.2022.105966_b0150","first-page":"129","article-title":"Evaluation of the anticancer property of a new alpha-methylene-gamma-lactone derivative of phthalimide","volume":"42","author":"Sanyal","year":"1995","journal-title":"Neoplasma"},{"key":"10.1016\/j.bioorg.2022.105966_b0155","doi-asserted-by":"crossref","first-page":"3928204","DOI":"10.1155\/2020\/3928204","article-title":"Synthesis of phthalimide imine derivatives as a potential anticancer agent","volume":"2020","author":"Abdulrahman","year":"2020","journal-title":"J. Chem."},{"key":"10.1016\/j.bioorg.2022.105966_b0160","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1016\/j.bmc.2008.02.005","article-title":"Synthesis and anti-cancer activity of benzothiazole containing phthalimide on human carcinoma cell lines","volume":"16","author":"Kok","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.105966_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104819","article-title":"Effect of the dichloro-substitution on antiproliferative activity of phthalimide-thiazole derivatives, Rational design, synthesis, elastase, caspase 3\/7, and EGFR tyrosine kinase activity and molecular modeling study","volume":"110","author":"Donarska","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2022.105966_b0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104835","article-title":"Design of molecular hybrids of phthalimide-triazole agents with potent selective MCF-7\/HepG2 cytotoxicity: synthesis, EGFR inhibitory effect, and metabolic stability","volume":"111","author":"Ihmaid","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2022.105966_b0175","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bioorg.2017.12.013","article-title":"Novel 1,2,4-triazole derivatives as potential anticancer agents: design, synthesis, molecular docking and mechanistic studies","volume":"76","author":"El-Sherief","year":"2018","journal-title":"Bioorg. Chem."},{"issue":"18","key":"10.1016\/j.bioorg.2022.105966_b0180","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1080\/00397911.2020.1786125","article-title":"Utilization of cyanoacetohydrazide and 2-(1,3-dioxoisoindolin- 2-yl)acetyl chloride in the synthesis of some novel anti-proliferative heterocyclic compounds","volume":"50","author":"Hekal","year":"2020","journal-title":"Synth. Commun."},{"issue":"11","key":"10.1016\/j.bioorg.2022.105966_b0185","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1517\/17460440903341705","article-title":"Promise and challenges in drug discovery and development of hybrid anticancer drugs","volume":"4","author":"Gediya","year":"2009","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bioorg.2022.105966_b0190","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.2174\/092986707781058805","article-title":"Molecular hybridization: a useful tool in the design of new drug prototypes","volume":"14","author":"Junior","year":"2007","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.105966_b0195","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/jhet.5570230218","article-title":"On triazoles. V, Synthesis of 1-and 2-R1-3-R2, R3-amino-5-amino-1,2,4-triazoles","volume":"23","author":"Reiter","year":"1986","journal-title":"J. Heterocycl. Chem."},{"key":"10.1016\/j.bioorg.2022.105966_b0200","first-page":"617","article-title":"Synthesis, antimicrobial activity, DNA-binding affinity and molecular docking of certain 1,2,4-triazolo[1,5-a]pyrimidines as nalidixic acid isosteres","volume":"8","author":"Ghaly","year":"2012","journal-title":"J. Am. Sci."},{"issue":"9","key":"10.1016\/j.bioorg.2022.105966_b0205","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1016\/j.ejmech.2011.07.002","article-title":"Synthesis and biological evaluation of some novel cyclic-imides as hypoglycaemic, anti-hyperlipidemic agents","volume":"46","author":"Abdel-Aziz","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.105966_b0210","article-title":"Synthesis and antitumor activity of certain new substituted 1H-isoindoledione derivatives","volume":"30","author":"Al-Obaid","year":"1999","journal-title":"Chem. Inform."},{"key":"10.1016\/j.bioorg.2022.105966_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104098","article-title":"Exploiting the 4-hydrazinobenzoic acid moiety for the development of anticancer agents: Synthesis and biological profile","volume":"102","author":"Abuelizz","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2022.105966_b0220","first-page":"1","article-title":"Cyanoacetohydrazides in synthesis of heterocyclic compounds","volume":"376","author":"Hosseini","year":"2018","journal-title":"Top. Curr. Chem."},{"key":"10.1016\/j.bioorg.2022.105966_b0225","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2478\/acph-2013-0004","article-title":"Synthesis and anti-tumor evaluation of novel hydrazide-hydrazone derivatives","volume":"63","author":"Wardakhan","year":"2013","journal-title":"Acta Pharm."},{"key":"10.1016\/j.bioorg.2022.105966_b0230","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0022-1759(86)90368-6","article-title":"Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability","volume":"89","author":"Denizot","year":"1986","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bioorg.2022.105966_b0235","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"issue":"6","key":"10.1016\/j.bioorg.2022.105966_b0240","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1517\/17460441.3.6.607","article-title":"The challenge of selecting protein kinase assays for lead discovery optimization","volume":"3","author":"Ma","year":"2008","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.bioorg.2022.105966_b0245","article-title":"Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R\/T790M\/C797S mutant EGFR tyrosine kinase inhibitors","volume":"186","author":"Lei","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.105966_b0250","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ejmech.2013.04.006","article-title":"Synthesis, interaction with DNA, cytotoxicity, cell cycle arrest and apoptotic inducing properties of ruthenium(II) molecular \u201clight switch\u201d complexes","volume":"64","author":"Devi","year":"2013","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105966_b0255","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.fct.2003.08.014","article-title":"Baicalein induced in vitro apoptosis undergo caspases activity in human promyelocytic leukemia HL- 60 cells","volume":"42","author":"Li","year":"2004","journal-title":"Food Chem. Toxicol."},{"issue":"2","key":"10.1016\/j.bioorg.2022.105966_b0260","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0304-3835(98)00253-5","article-title":"Induction of apoptosis in HL-60 cells by pungent vanilloids, [6]-gingerol and [6]-paradol","volume":"134","author":"Lee","year":"1998","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.bioorg.2022.105966_b0265","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1021\/ic701735q","article-title":"Luminescent biological probes derived from ruthenium(II) estradiol polypyridine complexes","volume":"47","author":"Lo","year":"2008","journal-title":"Inorg. Chem."},{"key":"10.1016\/j.bioorg.2022.105966_b0270","series-title":"Theory and practice of histological techniques","author":"Banchroft","year":"1996"},{"issue":"1","key":"10.1016\/j.bioorg.2022.105966_b0275","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1089\/nat.2011.0312","article-title":"Local delivery of chitosan\/VEGF siRNA nanoplexes reduces angiogenesis and growth of breast cancer in vivo","volume":"22","author":"\u015ealva","year":"2012","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/j.bioorg.2022.105966_b0280","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0076-6879(09)67012-9","article-title":"The basic concepts of molecular modeling","volume":"467","author":"Saxena","year":"2009","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.bioorg.2022.105966_b0285","doi-asserted-by":"crossref","first-page":"46265","DOI":"10.1074\/jbc.M207135200","article-title":"Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor","volume":"277","author":"Stamos","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2022.105966_b0290","unstructured":"MOE 2015.10 of Chemical Computing Group. Inc. https:\/\/www.chemcomp.com\/."},{"issue":"4","key":"10.1016\/j.bioorg.2022.105966_b0295","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"issue":"12","key":"10.1016\/j.bioorg.2022.105966_b0300","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.105966_b0305","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1021\/ci500588j","article-title":"DataWarrior: an open-source program for chemistry aware data visualization and analysis","volume":"55","author":"Sander","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.bioorg.2022.105966_b0310","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jhet.5570190534","article-title":"On triazoles. I. The reaction of N-cyanocarbonimidodithioic acid diesters with hydrazines","volume":"19","author":"Reiter","year":"1982","journal-title":"J. Heterocycl. Chem."},{"key":"10.1016\/j.bioorg.2022.105966_b0315","unstructured":"A.D. Baron, M.S. Fineman, N.R. Beeley, Elcelyx Therapeutics Inc, assignee. Compositions and methods of treating metabolic disorders, U.S. patent (2015) 9211263."},{"issue":"3","key":"10.1016\/j.bioorg.2022.105966_b0320","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1021\/jm00123a013","article-title":"5-(1-Piperazinyl)-1H-1,2,4-triazol-3-amines as antihypertensive agents","volume":"32","author":"Meyer","year":"1989","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2022.105966_b0325","doi-asserted-by":"crossref","unstructured":"Hughes, K. Gordon, Binuclear isomerism of diphenyl type, J. Pro. \u2013 R. Soc. N. S. W.71 (1938) 406-420.","DOI":"10.5962\/p.360213"},{"key":"10.1016\/j.bioorg.2022.105966_b0330","unstructured":"G. John, L. Xianfeng, L. Haixia, N. Isabel, Q. Zongxing, S. Virginie, T. Guozhi, W. Guolong, Preparation of pyridazinone-based broad spectrum anti-influenza drugs, WO 2018001948 (2018) A1 20180104."},{"key":"10.1016\/j.bioorg.2022.105966_b0335","unstructured":"S. Beckmann, E. Schefczik, Preperation of N-aminopyridones, U.S. patent (1995) 5466812."},{"key":"10.1016\/j.bioorg.2022.105966_b0340","first-page":"127","article-title":"Structure and reactions of cyclohexylidenecyanoacetic ester","volume":"1","author":"Vargha","year":"1962","journal-title":"J. Stud. Univ. Babes-Bolyai. Math."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206822003716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206822003716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T08:34:35Z","timestamp":1758616475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206822003716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":68,"alternative-id":["S0045206822003716"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2022.105966","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New phthalimide-based derivatives as EGFR-TK inhibitors: Synthesis, biological evaluation, and molecular modeling study","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2022.105966","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105966"}}